Sign In
Buy FEMY
$2.86
-0.0500 (-1.72%)
At Close: Jul 31, 2026
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
09:20am, Wednesday, 19'th Mar 2025
Femasys continues to expand access and market share for its first-line infertility treatment option Femasys continues to expand access and market share for its first-line infertility treatment option
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
09:00am, Tuesday, 18'th Mar 2025
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -
First-in-world approval of FemBloc delivery system for women seeking permanent birth control First-in-world approval of FemBloc delivery system for women seeking permanent birth control
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOB
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
09:00am, Tuesday, 11'th Feb 2025
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disrup
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
08:30am, Thursday, 30'th Jan 2025
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception European patents expand coverage for both esse
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
08:30am, Thursday, 16'th Jan 2025
FemaSeed® patent application provides additional coverage for Femasys' therapeutic option for women seeking infertility solution
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effect
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
10:45am, Tuesday, 12'th Nov 2024
Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago.
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
08:30am, Tuesday, 12'th Nov 2024
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
08:30am, Friday, 01'st Nov 2024
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic
Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program
08:30am, Thursday, 10'th Oct 2024
Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
08:30am, Wednesday, 02'nd Oct 2024
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-off
Femasys Announces Infertility Clinic Customers from Coast to Coast
08:30am, Wednesday, 18'th Sep 2024
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
08:30am, Wednesday, 11'th Sep 2024
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab
